Multimodal Treatment of Hepatocellular Carcinoma (HCC)

Sturm, J.; Keese, Michael

doi:10.1159/000077982

Cited by 18 publications

(16 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). The concept of multimodal therapeutic strategies has become a clinical reality in the effective treatment of HCC [21,22]. In this article, we review the current status of RFA-combination multimodal therapies in HCC management.…”

Section: Introductionmentioning

confidence: 99%

Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status

2016

View full text Add to dashboard Cite

Radiofrequency ablation (RFA) is widely accepted as a first-line interventional oncology approach for hepatocellular carcinoma (HCC) and has the advantages of high treatment efficacy and low complication risk. Local control rates equivalent to hepatic resection can be reached by RFA alone when treating small HCCs (<2 cm) in favorable locations. However, local tumor progression and recurrence rates with RFA monotherapy increase sharply when treating larger lesions (>3 cm). To address this clinical problem, recent efforts have focused on multimodel management of HCC by combining RFA with different techniques, including percutaneous ethanol injection, transarterial chemo-embolization, targeted molecular therapy, nanoparticle-mediated therapy, and immunotherapy. The combination strategy indeed leads to better outcomes in comparison to RFA alone. In this article, we review the current status of RFA-combined multimodal therapies in the management of HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status

2016

View full text Add to dashboard Cite

show abstract

“…Although improvement in survival with available treatments has been reported, HCC mostly engenders a poor prognosis, with a [60% recurrence rate within 5 years after resection due to invasion-related spreading [1,2]. The poor treatment outcome and dismal prognosis make research on HCC metastasis a high priority.…”

Section: Introductionmentioning

confidence: 99%

Role of PKCβ in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target

Guo

Kang

et al. 2008

Clin Exp Metastasis

View full text Add to dashboard Cite

Considerable interests have recently been focused on mechanism of human hepatocellular carcinoma (HCC) metastasis-the most fundamental characteristics of HCC and the ultimate cause of most HCC mortality, so screening more potential early prognostic marker and therapeutic target is urgent. In this study, we screened genome of three HCC cell lines with consistently increased metastatic potentials and sharing same genetic background, through DNA microarray and found consecutively up-regulated expression of PKCbeta in these cell lines compared to others PKCs, which was reconfirmed by real time RT-PCR and western blot analysis. Moreover, it was found, after efficient silence of PKCbeta by RNAi assay or inhibition of PKCbeta activity by a specific inhibitor LY317615, migration and invasion of HCC cells significantly decreased. In addition, depletion of PKCbeta protein significantly reversed the enhancement of PMA-stimulated HCC migration and invasion ability in vitro. All the data suggest a key role of PKCbeta in HCC motility and PKCbeta may be a potential therapeutic target.

show abstract

“…Surgical resection of HCC is still the treatment of choice in patients with good residual liver function. However, recurrence-free 5-year survival after curative resection is low (33%) [2]. New remedies would possibly depend on advances in basic research [3].…”

Section: Introductionmentioning

confidence: 99%

Growth Arrest and Apoptosis of the Human Hepatocellular Carcinoma Cell Line Bel-7402 Induced by Melittin

Bai

Gu²,

Zhang³

et al. 2006

Oncol Res Treat

View full text Add to dashboard Cite

Objective: The aim of this study was to investigate the cellular effects of melittin on the growth and apoptosis of human hepatocellular carcinoma (HCC) cells and to provide the molecular mechanism for potential application of a recombinant adenovirus carrying the melittin gene (Ad-rAFP-Mel) in the treatment of liver cancer. Methods: Human HCC cells (BEL-7402) were infected with Ad-rAFPMel at different times. In vitro cell growth was determined by MTT assay. Cellular apoptosis was evaluated quantitatively and qualitatively by phase-contrast microscopy, transmission electron microscopy, DNA ladder electrophoresis, TUNEL staining and flow cytometry. Results: Ad-rAFP-Mel infection had an inhibitory effect on the proliferation of BEL-7402 cells. The morphological changes of apoptosis were confirmed by microscopy and DNA electrophoresis. The ultrastructural characteristics of apoptotic cells, such as chromatin condensation and nuclear fragmentation, were also observed by electron microscopy in the Ad-rAFP-Mel-infected cells. Ad-rAFPMel infection markedly induced cellular apoptosis, and Fas expression on Bel-7402 cells infected by Ad-rAFPMel was up-regulated. Conclusion: The fact that melittin can induce apoptosis of the HCC cell line BEL-7402 leads us to consider adenovirus-mediated delivery of melittin as a promising approach for the treatment of HCC. However, the underlying mechanism needs to be further investigated.

show abstract

Multimodal Treatment of Hepatocellular Carcinoma (HCC)

Cited by 18 publications

References 78 publications

Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status

Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status

Role of PKCβ in hepatocellular carcinoma cells migration and invasion in vitro: a potential therapeutic target

Growth Arrest and Apoptosis of the Human Hepatocellular Carcinoma Cell Line Bel-7402 Induced by Melittin

Contact Info

Product

Resources

About